Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas was written by Dimou, Maria;Papageorgiou, Sotirios G.;Stavroyianni, Niki;Katodritou, Eirini;Tsirogianni, Maria;Kalpadakis, Christina;Banti, Anastasia;Arapaki, Maria;Iliakis, Theodoros;Bouzani, Maria;Verrou, Eugenia;Spanoudakis, Emmanouil;Giannouli, Stavroula;Marinakis, Theodoros;Mandala, Evdokia;Mparmparousi, Despoina;Sachanas, Sotirios;Dalekou-Tsolakou, Maria;Hatzimichael, Eleftheria;Vadikolia, Chryssa;Violaki, Vasiliki;Poziopoulos, Christos;Tsirkinidis, Pantelis;Chatzileontiadou, Sofia;Vervessou, Elissavet;Ximeri, Maria;Sioni, Anastasia;Konstantinidou, Pavlina;Kyrtsonis, Marie-Christine;Siakantaris, Marina P.;Angelopoulou, Maria K.;Pappa, Vassiliki;Konstantopoulos, Kostas;Panayiotidis, Panayiotis;Vassilakopoulos, Theodoros P.. And the article was included in Hematological Oncology in 2021.Reference of 16506-27-7 The following contents are mentioned in the article:
Transplant-ineligible relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) patients represent an unmet medical need. Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADG), with bendamustine- rituximab(BR) has recently gained approval for these patients, both in the USA and Europe, based on the GO29365 phase IIb trial. Real-life data with Pola are extremely limited. We report the outcomes of 61 Greek patients, who received Pola-(B)R mainly within a compassionate use program. Treatment was given for up to six 21-day cycles. Bendamustine was omitted in three cases due to previous short-lived responses. Fourty-nine rrDLBCL(efficacy cohort-EC) and 58 rr aggressive B-NHL (safety cohort-SC) patients received at least 1 Pola-BR cycle. Twenty-one (43%) patients of the EC responded with 12/49 (25%) CR and 9/49 (18%) PR as best response. Median progression-free survival, overall survival and duration of response were 4.0, 8.5, and 8.5 mo resp., while 55% of patients experienced a grade â? adverse event, mainly hematol. Treatment discontinuations and death during treatment were mainly due to disease progression. Twenty-two (41%) patients received further treatment; 11/22 are still alive, including one after CAR-T cells, and two after stem cell transplantation. Our data confirm that Pola-BR is a promising treatment for rrDLBCL patients, inducing an adequate response rate with acceptable toxicity. Pola-BR could be used as bridging therapy before further consolidative treatments. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Reference of 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem